A recent Breaking Defense article discussed a new anti-aging effort devised by the United States Special Operations Command (SOCOM). Apparently the Army unit is expected to begin clinical trials for a pill meant to combat the degenerative effects of aging and injury for “improved human performance.” SOCOM has partnered with Metro International Biotech, LLC, a private biotech laboratory, for the pill’s development. Since its launch in 2018, SOCOM has spent $2.8 million on the effort.
The special sauce is MetroBiotech’s development of proprietary precursor compounds for nicotinamide adenine dinucleotide (NAD+), which is linked to ageing and a variety of diseases. As people age, their NAD+ levels decline, but it can be mitigated, and the pill aims to do just that.
